|
FGFR4 |
fibroblast growth factor receptor 4 |
- PI3K Cascade
- PIP3 activates AKT signaling
- betaKlotho-mediated ligand binding
- FGFR4 mutant receptor activation
- FGFR4 ligand binding and activation
- Constitutive Signaling by Aberrant PI3K in Cancer
- Phospholipase C-mediated cascade; FGFR4
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR4 signaling
- Signaling by FGFR4 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- Heparin
- Ponatinib
- Lenvatinib
- Erdafitinib
- Pemigatinib
|
|
|
XPO1 |
exportin 1 |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Rev-mediated nuclear export of HIV RNA
- NEP/NS2 Interacts with the Cellular Export Machinery
- Downregulation of TGF-beta receptor signaling
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- Deactivation of the beta-catenin transactivating complex
- HuR (ELAVL1) binds and stabilizes mRNA
- RHO GTPases Activate Formins
- MAPK6/MAPK4 signaling
- Mitotic Prometaphase
- Cyclin A/B1/B2 associated events during G2/M transition
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- EML4 and NUDC in mitotic spindle formation
|
|
|
|
PDGFRA |
platelet derived growth factor receptor alpha |
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Imatinib-resistant PDGFR mutants
- Sunitinib-resistant PDGFR mutants
- Regorafenib-resistant PDGFR mutants
- Sorafenib-resistant PDGFR mutants
- PDGFR mutants bind TKIs
|
- Becaplermin
- Imatinib
- Sunitinib
- XL820
- Olaratumab
- Pazopanib
- Midostaurin
- Regorafenib
- Ponatinib
- Lenvatinib
- Nintedanib
- Foreskin keratinocyte (neonatal)
- Fostamatinib
- Erdafitinib
- Amuvatinib
- Ripretinib
|
|
|
FZR1 |
fizzy and cell division cycle 20 related 1 |
- Autodegradation of Cdh1 by Cdh1:APC/C
- SCF-beta-TrCP mediated degradation of Emi1
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
- Regulation of APC/C activators between G1/S and early anaphase
- Phosphorylation of Emi1
- Senescence-Associated Secretory Phenotype (SASP)
- CDK-mediated phosphorylation and removal of Cdc6
- Cyclin A:Cdk2-associated events at S phase entry
- Transcriptional Regulation by VENTX
- Aberrant regulation of mitotic exit in cancer due to RB1 defects
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
HGS |
hepatocyte growth factor-regulated tyrosine kinase substrate |
- EGFR downregulation
- Lysosome Vesicle Biogenesis
- Ub-specific processing proteases
- Negative regulation of MET activity
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- InlB-mediated entry of Listeria monocytogenes into host cell
- Endosomal Sorting Complex Required For Transport (ESCRT)
- Inhibition of membrane repair
- Prevention of phagosomal-lysosomal fusion
- RHOBTB3 ATPase cycle
|
|
|
|
ARAF |
A-Raf proto-oncogene, serine/threonine kinase |
- RAF activation
- MAP2K and MAPK activation
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by MRAS-complex mutants
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
HIF1A |
hypoxia inducible factor 1 subunit alpha |
- Regulation of gene expression by Hypoxia-inducible Factor
- Cellular response to hypoxia
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- NOTCH1 Intracellular Domain Regulates Transcription
- Circadian Clock
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- PTK6 Expression
- PTK6 promotes HIF1A stabilization
- Neddylation
|
- Carvedilol
- Hydralazine
- 2-Methoxyestradiol
- ENMD-1198
- PX-478
- FG-2216
|
|
|
SPTBN1 |
spectrin beta, non-erythrocytic 1 |
- Nephrin family interactions
- NCAM signaling for neurite out-growth
- NCAM signaling for neurite out-growth
- Interaction between L1 and Ankyrins
- Interaction between L1 and Ankyrins
- RAF/MAP kinase cascade
- COPI-mediated anterograde transport
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 fusion proteins
|
- Calcium
- 1D-myo-inositol 1,4,5-trisphosphate
|
|
|
AURKA |
aurora kinase A |
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Regulation of PLK1 Activity at G2/M Transition
- SUMOylation of DNA replication proteins
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- Regulation of TP53 Activity through Phosphorylation
- FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
- AURKA Activation by TPX2
- Interaction between PHLDA1 and AURKA
|
- Phosphonothreonine
- AT9283
- CYC116
- Alisertib
- SNS-314
- Cenisertib
- Enzastaurin
- 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
- AKI-001
- 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea
- 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea
- N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE
- N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
- 2-(1H-pyrazol-3-yl)-1H-benzimidazole
- N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
- Fostamatinib
- MLN8054
|
|
|
CDK6 |
cyclin dependent kinase 6 |
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Cyclin D associated events in G1
- Regulation of RUNX1 Expression and Activity
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
|
- Alvocidib
- (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol
- Fisetin
- Palbociclib
- Ribociclib
- Abemaciclib
|
|
|
KDM1A |
lysine demethylase 1A |
- HDACs deacetylate histones
- HDMs demethylate histones
- Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
- Regulation of PTEN gene transcription
- Estrogen-dependent gene expression
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- Potential therapeutics for SARS
- Factors involved in megakaryocyte development and platelet production
|
|
|
|
MDM4 |
MDM4 regulator of p53 |
- Oxidative Stress Induced Senescence
- Oncogene Induced Senescence
- Ub-specific processing proteases
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Methylation
- Stabilization of p53
|
|
|
|
ARNT |
aryl hydrocarbon receptor nuclear translocator |
- Regulation of gene expression by Hypoxia-inducible Factor
- PPARA activates gene expression
- Phase I - Functionalization of compounds
- Endogenous sterols
- Xenobiotics
- Aryl hydrocarbon receptor signalling
|
|
|
|
CD44 |
CD44 molecule (Indian blood group) |
- Degradation of the extracellular matrix
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Hyaluronan uptake and degradation
- Neutrophil degranulation
- Interferon gamma signaling
|
- Bivatuzumab
- Hyaluronic acid
|
|
|
EIF3B |
eukaryotic translation initiation factor 3 subunit B |
- L13a-mediated translational silencing of Ceruloplasmin expression
- Translation initiation complex formation
- Formation of a pool of free 40S subunits
- Formation of the ternary complex, and subsequently, the 43S complex
- Ribosomal scanning and start codon recognition
- GTP hydrolysis and joining of the 60S ribosomal subunit
|
|
|
|
EPHA2 |
EPH receptor A2 |
- EPH-Ephrin signaling
- EPH-Ephrin signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- EPH-ephrin mediated repulsion of cells
|
- Dasatinib
- Phosphoaminophosphonic Acid-Adenylate Ester
- Regorafenib
- Fostamatinib
|
|
|
PXN |
paxillin |
- GAB1 signalosome
- VEGFA-VEGFR2 Pathway
- Smooth Muscle Contraction
- Localization of the PINCH-ILK-PARVIN complex to focal adhesions
- Regulation of cytoskeletal remodeling and cell spreading by IPP complex components
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
|
|
|
CDKN2B |
cyclin dependent kinase inhibitor 2B |
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Cyclin D associated events in G1
|
|
- Malignant pleural mesothelioma
- Osteosarcoma
- Type II diabetes mellitus
|
|
EMD |
emerin |
- Nuclear Envelope Breakdown
- Initiation of Nuclear Envelope (NE) Reformation
- Depolymerisation of the Nuclear Lamina
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
|
|
- Emery-Dreifuss muscular dystrophy
|
|
SDCBP |
syndecan binding protein |
- Ephrin signaling
- Neurofascin interactions
- RIPK1-mediated regulated necrosis
- Regulation of necroptotic cell death
- Neutrophil degranulation
|
|
|